Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-14 6:18 pm Purchase | 13G | VISTAGEN THERAPEUTICS INC VTGN | CITADEL ADVISORS LLC | 1,600,768 5.8% | 6,832 (+0.43%) | View |
| 2024-02-14 4:51 pm Purchase | 13G | VISTAGEN THERAPEUTICS INC VTGN | Nantahala Capital Management LLC | 2,797,588 9.9% | 2,797,588 (New Position) | View |
| 2024-02-14 4:39 pm Unchanged | 13G | VISTAGEN THERAPEUTICS INC VTGN | GREAT POINT PARTNERS LLC | 2,792,927 9.99% | 0 (Unchanged) | View |
| 2024-02-14 08:56 am Sale | 13G | VISTAGEN THERAPEUTICS INC VTGN | Point72 Asset Management L.P. | 822,334 3% | -743,495 (-47.48%) | View |
| 2024-02-13 5:17 pm Purchase | 13G | VISTAGEN THERAPEUTICS INC VTGN | VANGUARD GROUP INC | 1,834,512 6.79% | 1,834,512 (New Position) | View |
| 2023-10-16 4:37 pm Purchase | 13G | VISTAGEN THERAPEUTICS INC VTGN | TCG Crossover GP II LLC | 2,702,157 9.9% | 2,702,157 (New Position) | View |
| 2023-10-16 4:34 pm Purchase | 13G | VISTAGEN THERAPEUTICS INC VTGN | BIOTECHNOLOGY VALUE FUND L P | 2,777,245 9.99% | 2,777,245 (New Position) | View |
| 2023-10-16 4:01 pm Purchase | 13G | VISTAGEN THERAPEUTICS INC VTGN | CITADEL ADVISORS LLC | 1,593,936 5.7% | 1,593,936 (New Position) | View |
| 2023-10-12 4:04 pm Purchase | 13G | VISTAGEN THERAPEUTICS INC VTGN | GREAT POINT PARTNERS LLC | 2,792,927 9.99% | 2,792,927 (New Position) | View |
| 2023-10-06 4:05 pm Purchase | 13G | VISTAGEN THERAPEUTICS INC VTGN | COMMODORE CAPITAL LP | 2,367,884 9.9% | 792,884 (+50.34%) | View |
| 2023-10-05 4:47 pm Purchase | 13G | VISTAGEN THERAPEUTICS INC VTGN | Point72 Asset Management L.P. | 1,565,829 5.6% | 1,565,829 (New Position) | View |
| 2023-08-09 4:15 pm Purchase | 13G | VISTAGEN THERAPEUTICS INC VTGN | COMMODORE CAPITAL LP | 1,575,000 19.7% | 1,575,000 (New Position) | View |
| 2023-07-07 4:35 pm Sale | 13G | VISTAGEN THERAPEUTICS, INC. CO VTGN | BlackRock Inc. BLK | 0 0% | -12,267,968 (Position Closed) | View |
| 2023-02-14 5:20 pm Sale | 13G | VISTAGEN THERAPEUTICS, INC. CO VTGN | ORBIMED ADVISORS LLC | 0 0% | -10,519,240 (Position Closed) | View |
| 2023-02-14 4:06 pm Sale | 13G | VISTAGEN THERAPEUTICS, INC. CO VTGN | COMMODORE CAPITAL LP | 0 0% | -10,455,910 (Position Closed) | View |
| 2023-02-14 3:32 pm Sale | 13G | VISTAGEN THERAPEUTICS, INC. CO VTGN | ACUTA CAPITAL PARTNERS LLC | 0 0% | -11,736,283 (Position Closed) | View |
| 2023-02-01 4:54 pm Purchase | 13G | VISTAGEN THERAPEUTICS, INC. CO VTGN | BlackRock Inc. BLK | 12,267,968 5.9% | 373,775 (+3.14%) | View |
| 2023-02-01 1:49 pm Sale | 13G | VISTAGEN THERAPEUTICS, INC. CO VTGN | FRANKLIN RESOURCES INC BEN | 0 0% | -10,117,999 (Position Closed) | View |
| 2022-08-12 5:15 pm Sale | 13D | VISTAGEN THERAPEUTICS, INC. CO VTGN | Growth Equity Opportunities 17 LLC | 0 0% | -16,302,596 (Position Closed) | View |
| 2022-07-08 4:05 pm Purchase | 13G | VISTAGEN THERAPEUTICS, INC. CO VTGN | Venrock Healthcare Capital Partners II L.P. | 20,697,286 10% | 4,650,000 (+28.98%) | View |